We are live on
!
Find out more
SM
SG3 Management Portfolio holdings
AUM
$6.45K
1-Year Est. Return
61.81%
This Fund
S&P 500
This Quarter
Est. Return
+6.6%
1 Year Est. Return
-61.81%
3 Year Est. Return
-38.3%
5 Year Est. Return
-6.2%
10 Year Est. Return
–
AUM
$3.3B
AUM Growth
+$481M
(+17%)
Cap. Flow
+$512M
Cap. Flow
% of AUM
15.52%
Top 10 Holdings %
Top 10 Hldgs %
30.72%
Holding
1,380
New
403
Increased
148
Reduced
188
Closed
428
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Alphabet (Google) Class C
GOOG
|
+$41.4M |
| 2 |
XLRN
Acceleron Pharma
XLRN
|
+$7.85M |
| 3 |
Bausch Health
BHC
|
+$7.4M |
| 4 |
Albemarle
ALB
|
+$6.62M |
| 5 |
Alnylam Pharmaceuticals
ALNY
|
+$6.61M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Alphabet (Google) Class A
GOOGL
|
+$24.4M |
| 2 |
Jazz Pharmaceuticals
JAZZ
|
+$10M |
| 3 |
Amgen
AMGN
|
+$7.37M |
| 4 |
Cracker Barrel
CBRL
|
+$5.6M |
| 5 |
Costco
COST
|
+$5.44M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 3.28% |
| 2 | Communication Services | 1.55% |
| 3 | Technology | 0.91% |
| 4 | Consumer Discretionary | 0.74% |
| 5 | Financials | 0.43% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
351
AES
AES
$10.6B
| $1.6M | 0.05% |
70,000
-30,000
| -30% | -$729K |
|
352
PUT
Ascendis Pharma A/S
ASND
$16.5B
| $1.59M | 0.05% |
10,000
| – | – |
|
|
ALLK
353
PUT
DELISTED
Allakos
ALLK
| $1.59M | 0.05% |
+15,000
| New | +$1.34M |
|
354
PUT
Visa
V
$677B
| $1.56M | 0.05% |
7,000
-4,000
| -36% | -$938K |
|
355
Teva Pharmaceuticals
TEVA
$40.4B
| $1.56M | 0.05% |
160,000
| – | – |
|
356
CALL
AvePoint
AVPT
$2.76B
| $1.56M | 0.05% |
183,400
-56,600
| -24% | -$563K |
|
357
CALL
Starbucks
SBUX
$119B
| $1.55M | 0.05% |
+14,100
| New | +$1.65M |
|
358
PUT
Yeti Holdings
YETI
$3.87B
| $1.54M | 0.05% |
18,000
| – | – |
|
359
CALL
Krystal Biotech
KRYS
$10.7B
| $1.54M | 0.05% |
+29,500
| New | +$1.75M |
|
360
CALL
Kura Oncology
KURA
$793M
| $1.54M | 0.05% |
82,000
+47,000
| +134% | +$886K |
|
361
Incyte
INCY
$25.8B
| $1.51M | 0.05% |
+22,000
| New | +$1.67M |
|
362
PUT
Quince Therapeutics
QNCX
$21.5M
| $1.51M | 0.05% |
+83
| New | +$1.32M |
|
363
PUT
Viatris
VTRS
$20.8B
| $1.51M | 0.05% |
111,600
+18,000
| +19% | +$255K |
|
364
PUT
Nutanix
NTNX
$16.1B
| $1.51M | 0.05% |
+40,000
| New | +$1.51M |
|
|
HYZN
365
CALL
DELISTED
Hyzon Motors Inc. Class A Common Stock
HYZN
| $1.51M | 0.05% |
+4,340
| New | +$1.88M |
|
366
Aurinia Pharmaceuticals
AUPH
$1.95B
| $1.5M | 0.05% |
68,000
+58,000
| +580% | +$920K |
|
367
CALL
Verra Mobility
VRRM
$775M
| $1.5M | 0.05% |
+99,500
| New | +$1.52M |
|
368
Workday
WDAY
$41.5B
| $1.5M | 0.05% |
+6,000
| New | +$1.49M |
|
369
CALL
Advanced Micro Devices
AMD
$700B
| $1.49M | 0.05% |
14,500
+4,000
| +38% | +$409K |
|
370
CALL
Fate Therapeutics
FATE
$275M
| $1.48M | 0.04% |
+25,000
| New | +$1.96M |
|
|
371
PUT
Fate Therapeutics
FATE
$275M
| $1.48M | 0.04% |
+25,000
| New | +$1.96M |
|
372
CALL
Domino's
DPZ
$11.9B
| $1.48M | 0.04% |
+3,100
| New | +$1.57M |
|
373
Prudential Financial
PRU
$42.6B
| $1.47M | 0.04% |
14,000
-4,500
| -24% | -$464K |
|
374
Phillips 66
PSX
$82.9B
| $1.47M | 0.04% |
+21,000
| New | +$1.52M |
|
|
DNMR
375
CALL
DELISTED
Danimer Scientific, Inc.
DNMR
| $1.47M | 0.04% |
+2,250
| New | +$1.65M |
|
Similar funds
EAM
CAM
CCM
GPCM
MAM
BGCI
TPL
RC
SG3 Management's Q3 2021 Portfolio in Review
As of Q3 2021, SG3 Management held 1,380 positions worth $3.3B, up 17% from $2.82B the previous quarter. Its ten largest holdings account for 31% of the portfolio.
SG3 Management deployed $512M of net new capital in Q3 2021, opening 403 new positions and adding to 148 existing holdings. Its largest new stake was Alphabet (Google) Class C: 300,000 shares worth $40M.
By sector, the portfolio is most concentrated in Healthcare at 3.3% of assets, up from 2.3% a quarter earlier, followed by Communication Services and Technology.
On the sell side, the largest reduction was Bank of America, an estimated $4.85M trimmed.
- SG3 Management's largest Q3 2021 buy was Alphabet (Google) Class C: 300,000 shares worth $40M.
- SG3 Management added most to Bausch Health in Q3 2021, an estimated $7.4M increase.
- SG3 Management's biggest Q3 2021 reduction was Bank of America, cutting an estimated $4.85M.
- SG3 Management fully exited Alphabet (Google) Class A in Q3 2021, selling an estimated $24.4M.
- SG3 Management's ten largest holdings make up 31% of its $3.3B portfolio in Q3 2021.
- SG3 Management opened 403 new positions and closed 428 in Q3 2021.
- SG3 Management's portfolio value rose 17% quarter-over-quarter to $3.3B.
Based on SG3 Management's 13F filing for Q3 2021, filed 15 Nov 2021.